Drug combination for obesity: First do no harm with anti-obesity and other drugs

BMJ (Online)

Volumn 346, Issue 7910, 2013, Pages

  Toussaint, Bruno ^a  

^a Prescrire International   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALMITRINE; AMFEBUTAMONE PLUS NALTREXONE; ANTIOBESITY AGENT; DICLOFENAC; DOMPERIDONE; IRON DEXTRAN; LIRAGLUTIDE; LISDEXAMFETAMINE; LORCASERIN; ORAL CONTRACEPTIVE AGENT; PHENTERMINE PLUS TOPIRAMATE; TETRAZEPAM;

DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH HAZARD; HEART ARRHYTHMIA; HUMAN; LETTER; MEDICAL DECISION MAKING; MENTAL DISEASE; METABOLIC ACIDOSIS; OBESITY; PATIENT SAFETY; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; UNITED STATES; WEIGHT REDUCTION; DRUG COMBINATION;

ANTI-OBESITY AGENTS; DRUG THERAPY, COMBINATION; HUMANS; OBESITY; PATIENT SAFETY;

EID: 84878593764     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f3026     Document Type: Letter

References (6)

1. Taubes G. The science of obesity: what do we really know about what makes us fat? An essay by Gary Taubes. BMJ 2013;346:f1050. (16 April.)
2. European Medicines Agency. Refusal for the marketing authorisation for Qsiva (phentermine/topiramate). Questions and Answers. 2013. www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial- authorisation/human/002350/WC500139215.pdf.
3. Prescrire Editorial Staff. Topiramate+phentermine, an excessively dangerous appetite-supressant combination. Prescrire Int 2013;22:64-7.
4. Prescrire. Medicinal products used in weight control: first, do no harm! 2012. http://english.prescrire.org/en/79/207/46302/2374/1884/SubReportDetails. aspx.
5. SCRIP. Fragrance or folly: 15 drug events will resolve before April. Informa News 22 February 2013.
6. European Medicines Agency. PRAC: Agendas, minutes and highlights webpage. www.ema.europa.eu/ema/index.jsp?curl=pages/about-us/document-listing/document- listing-000353.jsp&mid=WC0b01ac05805a21cf.